Trafficking of G-protein-coupled receptors to the plasma membrane: Insights for pharmacoperone drugs

Trends in Endocrinology and Metabolism

Volumn 21, Issue 3, 2010, Pages 190-197

  Conn, P Michael ^a,b,c   Ulloa Aguirre, Alfredo ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Hospital Luis Castelazo Ayala   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; G PROTEIN COUPLED RECEPTOR; GONADORELIN RECEPTOR;

AMINO ACID SUBSTITUTION; BINDING SITE; CELL MEMBRANE; CELL TRANSPORT; DRUG RECEPTOR BINDING; GENE SEQUENCE; HUMAN; LIGAND BINDING; MUTATIONAL ANALYSIS; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW;

ANIMALS; CELL MEMBRANE; HUMANS; MODELS, BIOLOGICAL; PROTEIN FOLDING; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LHRH;

EID: 77949325574     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.11.003     Document Type: Review

References (61)

1. Lin J.C., Liu H.L. Protein conformational diseases: from mechanisms to drug designs. Curr. Drug Discov. Technol. 2006, 3:145-153.
2. Castro-Fernandez C., et al. Beyond the signal sequence: protein routing in health and disease. Endocr. Rev. 2005, 26:479-503.
3. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
4. Gregersen N. Protein misfolding disorders: pathogenesis and intervention. J. Inherit. Metab. Dis. 2006, 29:456-470.
5. Beglova N., Blacklow S.C. The LDL receptor: how acid pulls the trigger. Trends Biochem. Sci. 2005, 30:309-317.
6. Mendes H.F., et al. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med. 2005, 11:177-185.
7. O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet 2009, 373:1891-1904.
8. Bichet D.G. Nephrogenic diabetes insipidus. Adv. Chronic Kidney. Dis. 2006, 13:96-104.
9. Janovick J.A., et al. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J. Clin. Endocrinol. Metab. 2002, 87:3255-3262.
10. Fujiwara T.M., Bichet D.G. Molecular biology of hereditary diabetes insipidus. J. Am. Soc. Nephrol. 2005, 16:2836-2846.
11. Hermosilla R., et al. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 2004, 5:993-1005.
12. Conn P.M., et al. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol. Rev. 2007, 59:225-250.
13. Calebiro D., et al. Intracellular entrapment of wild-type TSH receptor by oligomerization with mutants linked to dominant TSH resistance. Hum. Mol. Genet. 2005, 14:2991-3002.
14. Ellgaard L., Helenius A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 2003, 4:181-191.
15. Sitia R., Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 2003, 426:891-894.
16. Hartl F.U., Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 2009, 16:574-581.
17. Conn P.M., et al. Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor. Mol. Endocrinol. 2006, 20:3035-3041.
18. Ulloa-Aguirre A., Conn P.M. Targeting of G protein-coupled receptors to the plasma membrane in health and disease. Front. Biosci. 2009, 14:973-994.
19. Conn P.M., et al. 'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation. J. Endocrinol. 2006, 190:13-16.
20. Wuller S., et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J. Biol. Chem. 2004, 279:47254-47263.
21. Lu M., et al. Endoplasmic reticulum degradation impedes olfactory G-protein coupled receptor functional expression. BMC Cell Biol. 2004, 5:34.
22. Pietila E.M., et al. Inefficient maturation of the rat luteinizing hormone receptor. A putative way to regulate receptor numbers at the cell surface. J. Biol. Chem. 2005, 280:26622-26629.
23. Ulloa-Aguirre A., et al. Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism. Hum. Reprod. Update 2004, 10:177-192.
24. Ulloa-Aguirre A., et al. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 2004, 5:821-837.
25. Millar R.P., et al. Gonadotropin-releasing hormone receptors. Endocr. Rev. 2004, 25:235-275.
26. Brothers S.P., et al. Conserved mammalian gonadotropin-releasing hormone receptor carboxyl terminal amino acids regulate ligand binding, effector coupling and internalization. Mol. Cell. Endocrinol. 2002, 190:19-27.
27. Lin X., et al. Addition of catfish gonadotropin-releasing hormone (GnRH) receptor intracellular carboxyl-terminal tail to rat GnRH receptor alters receptor expression and regulation. Mol. Endocrinol. 1998, 12:161-171.
28. Arora K.K., et al. Influence of a species-specific extracellular amino acid on expression and function of the human gonadotropin-releasing hormone receptor. Mol. Endocrinol. 1999, 13:890-896.
29. Janovick J.A., et al. Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: molecular basis of an evolved strategy. J. Biol. Chem. 2006, 281:8417-8425.
30. Ulloa-Aguirre A., et al. G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease. ACS Chem. Biol. 2006, 1:631-638.
31. Jardon-Valadez E., et al. Conformational effects of Lys191 in the human GnRHR: mutagenesis and molecular dynamics simulations studies. J. Endocrinol. 2009, 201:297-307.
32. Janovick J.A., et al. Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor. Mol. Endocrinol. 2009, 23:157-168.
33. Brothers S.P., et al. Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect. Mol. Endocrinol. 2004, 18:1787-1797.
34. Milligan G. G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim. Biophys. Acta 2007, 1768:825-835.
35. Conn P.M., et al. Conversion of a gonadotropin-releasing hormone antagonist to an agonist. Nature 1982, 296:653-655.
36. Bulenger S., et al. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 2005, 26:131-137.
37. Beaumont K.A., et al. Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum. Mol. Genet. 2007, 16:2249-2260.
38. McElvaine A.T., Mayo K.E. A dominant-negative human growth hormone-releasing hormone (GHRH) receptor splice variant inhibits GHRH binding. Endocrinology 2006, 147:1884-1894.
39. Leanos-Miranda A., et al. In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. J. Clin. Endocrinol. Metab. 2005, 90:3001-3008.
40. Persani L., et al. Technology Insight: modern methods to monitor protein-protein interactions reveal functional TSH receptor oligomerization. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:180-190.
41. Leanos-Miranda A., et al. Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans. J. Clin. Endocrinol. Metab. 2003, 88:3360-3367.
42. Knollman P.E., et al. Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropin-releasing hormone receptor mutants. J. Biol. Chem. 2005, 280:24506-24514.
43. Bernier V., et al. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol. Metab. 2004, 15:222-228.
44. Maya-Nunez G., et al. Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site. J. Clin. Endocrinol. Metab. 2002, 87:2144-2149.
45. Bernier V., et al. Pharmacological chaperone action on G-protein-coupled receptors. Curr. Opin. Pharmacol. 2004, 4:528-533.
46. Conn P.M., Janovick J.A. Drug development and the cellular quality control system. Trends Pharmacol. Sci. 2009, 30:228-233.
47. Pey A.L., et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest. 2008, 118:2858-2867.
48. Estrada L.D., Soto C. Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr. Pharm. Des. 2006, 12:2557-2567.
49. Bernier V., et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 2006, 17:232-243.
50. Janovick J.A., et al. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J. Pharmacol. Exp. Ther. 2003, 305:608-614.
51. Leskela T.T., et al. Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum. J. Biol. Chem. 2007, 282:23171-23183.
52. Beaumont K.A., et al. Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Hum. Mol. Genet. 2005, 14:2145-2154.
53. Jardon-Valadez E., et al. Modeling and molecular dynamics simulation of the human gonadotropin-releasing hormone receptor in a lipid bilayer. J. Phys. Chem. B 2008, 112:10704-10713.
54. Soderhall J.A., et al. Antagonist and agonist binding models of the human gonadotropin-releasing hormone receptor. Biochem. Biophys. Res. Commun. 2005, 333:568-582.
55. Janovick J.A., et al. Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine. Mol. Cell. Endocrinol. 2009, 298:84-88.
56. Huang Y., Breitwieser G.E. Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. J. Biol. Chem. 2007, 282:9517-9525.
57. Huhtaniemi I.T., Themmen A.P. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine 2005, 26:207-217.
58. Amiel J., et al. Hirschsprung disease, associated syndromes and genetics: a review. J. Med. Genet. 2008, 45:1-14.
59. Clark A.J., et al. Inherited ACTH insensitivity illuminates the mechanisms of ACTH action. Trends Endocrinol. Metab. 2005, 16:451-457.
60. Tao Y.X. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol. Cell. Endocrinol. 2005, 239:1-14.
61. Reiche E.M., et al. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr. Med. Chem. 2007, 14:1325-1334.